In conclusion, KRAS and EGFR mutations can be detected in peripheral blood as an alternative and supplement to tissue analysis; and quantitative levels of cfDNA, pmKRAS, and pmEGFR are associated to the clinical outcome of the surgical treatment of lung cancer. Here, KRAS is linked to lung cancer.